CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 408 · Search date 2026-07-17 · Methodology v0.6

Shoden® ashwagandha extract,
does it really help with Sleep quality, sleep onset, and nighttime awakenings?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Direct Shoden sleep evidence is one commercially linked trial, and KSM-66 studies are not replication of Shoden.
What the
research shows
Direct sleep evidence for Shoden consists of one randomized trial with 150 participants. Of these, 144 completed the six-week study; the primary endpoint was the subjective RSQ-W, actigraphy was secondary, and Arjuna Natural supplied the test product and placebo. The other four trials in the meta-analysis used KSM-66 and cannot be pooled as replication of Shoden, supporting C.
What the
ads claim
Marketing often treats ordinary ashwagandha powder, root extracts, and high-potency root-and-leaf Shoden as interchangeable, and converts stress reduction into an insomnia-treatment claim. The evidence supports a short-term adjunctive effect at a specific standardization and dose, not replacement of insomnia treatment or equal effects from all ashwagandha products.
*

Useful facts when choosing a product

  • In South Korea, Shoden® ashwagandha extract is distributed as individually recognized ingredient No. 2022-27, with an official daily intake of 120 mg.
  • The pivotal Shoden trial also used 120 mg/day for six weeks. Ordinary powder and products with other withanolide specifications are not dose-equivalent.
  • Korean regulatory guidance advises avoidance by infants, children, and pregnant or lactating people, and avoidance with sedative medicines.
  • Rare reports of liver injury and possible thyroid or sedative interactions are safety issues separate from the efficacy grade.
Gap Measurement · Verdict 408 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Deshpande 2020 randomized 150 adults with nonrestorative sleep to Shoden at 120 mg/day or placebo, and 144 completed six weeks. The primary endpoint was the subjective RSQ-W; actigraphy measures of sleep efficiency, total sleep time, sleep-onset latency, and wake after sleep onset were secondary. Arjuna Natural supplied Shoden and placebo capsules. In the 2021 meta-analysis by Cheah, this was the only Shoden trial and the other four used KSM-66. The Langade trial also used KSM-66 at 600 mg/day, not Shoden.

02

Why this is classified as C (50)

Direct Shoden evidence is limited to one commercially linked 150-participant, six-week trial with a subjective primary endpoint, and four KSM-66 trials are not same-product replication, supporting C with 50 points.

Counterpoint. This is separate from the stress axis in verdict 035 and from KSM-66 sleep evidence, neither of which is pooled into Shoden.

Rejudgment record. Reassessment (cross-check reflected) — Direct Shoden evidence is one six-week RCT with 150 randomized and 144 completers, a subjective RSQ-W primary endpoint, secondary actigraphy, and Arjuna Natural support; the other four trials used KSM-66

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Deshpande A et al. 2020Randomized double-blind placebo-controlled trial150Partly supported by the Shoden manufacturerRestorative-sleep questionnaire and actigraphy sleep-onset latency, sleep efficiency, total sleep time, and WASOShoden 120 mg/day for six weeks improved subjective sleep and several actigraphy measures versus placebo.Key
Cheah KL et al. 2021Systematic review and meta-analysis400Academic review; some included trials had manufacturer supportSleep quality and quantity, PSQI, sleep-onset latency, and WASOOnly one of five trials directly tested Shoden; the other four used KSM-66 and cannot count as Shoden replication.Key
Langade D et al. 2021Randomized double-blind placebo-controlled trial40Product linkage unclearPSQI, sleep-onset latency, total sleep time, WASO, and sleep efficiencySleep signals came from KSM-66 at 600 mg/day, not a direct Shoden trial.Supportive
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Deshpande A, Irani N, Balkrishnan R, Benny IR. A randomized, double blind, placebo controlled study to evaluate the effects of ashwagandha (Withania somnifera) extract on sleep quality in healthy adults. Sleep Med. 2020;72:28-36. PMID: 32540634. DOI: 10.1016/j.sleep.2020.03.012.
checked
Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843. PMID: 34559859. DOI: 10.1371/journal.pone.0257843.
checked
Langade D, Thakare V, Kanchi S, Kelgane S. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: a double-blind, randomized, parallel-group, placebo-controlled study. J Ethnopharmacol. 2021;264:113276. PMID: 32818573. DOI: 10.1016/j.jep.2020.113276.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Shoden® ashwagandha extract x sleep quality, sleep onset, and nighttime awakenings Evidence Grade C card
[Chamgap] Shoden® ashwagandha extract x sleep quality, sleep onset, and nighttime awakenings — Evidence Grade C·50. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/shoden-ashwagandha-sleep-quality-onset-awakenings/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.